从Kaplan-Meier (IPDfromKM) 方法重建的个人患者数据用于非劣势分析:一个新的潜在应用
Eugenia Piragine1,2, Sabrina Trippoli3, Sara Veneziano1
1Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
Methods and protocols
|February 25, 2025
概括
作为人工智能工具的IPDfromKM方法现在可以验证非劣势分析. 这种人工智能方法表明,与抗凝血剂相比,左心房附属器设备在心房的管理中没有劣势.
科学领域:
- 医疗信息学 医疗信息学
- 生物统计学 生物统计学
- 心脏病学 心脏病学
背景情况:
- IPDfromKM方法从卡普兰-梅尔曲线重建了个体患者的数据,以进行间接研究比较.
- 虽然它通常用于优势分析,但它在非劣势分析中的应用缺乏验证.
- 左心房尾闭塞装置已被确立为对心房的口服抗凝剂不劣.
研究的目的:
- 为了验证IPDfromKM方法用于非劣势分析.
- 利用现有的关于左心房附属器设备与心房动中口服抗凝剂的现有数据.
主要方法:
- 来自PubMed的随机对照试验 (RCT) 的系统综述.
- 使用R软件进行生存分析,比较Watchman和Amlet设备与华法林.
- 95%置信区间 (CI) 的危险比率 (HR) 是主要的结果指标.
主要成果:
- 分析证实,与华法林相比,Watchman (HR:1.23,95%CI:0.80-1.9) 和Amlet (HR:1.05,95%CI:0.61-1.80) 设备的不劣质.
- IPDfromKM方法成功支持了非劣等性假设.
结论:
- IPDfromKM方法已被验证用于非劣势分析.
- 这种人工智能方法为管理心房和其他疾病的决策提供了有价值的工具.
相关概念视频
Kaplan-Meier Approach
78
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
78
Comparing the Survival Analysis of Two or More Groups
118
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
118
Cancer Survival Analysis
320
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
320
Introduction To Survival Analysis
158
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
158
Actuarial Approach
53
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
53
Censoring Survival Data
55
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
55


